We investigated the risk factors for venous thrombosis in cancer patients with implantable ports undergoing chemotherapy. One hundred and seventy one ports were placed in a central ("chest ports") and 84 in a peripheral vein ("arm ports"), 181 received prophylactic nadroparin and 10 coumarin. Clinically overt thrombosis was confirmed by ultrasound or angiography. Catheter-related thrombosis incidence without anticoagulants was 28% in arm and 33% in chest ports, but with anticoagulants this was 32% in arm and only 1% in chest ports (odds ratio (OR) 34.8 95% confidence interval (CI) 7.3-165). Left-sided placement compared with right-sided and catheter tip position in the superior vena cava compared with right atrium were associated with a 3.5 respectively 2.6-fold increased risk. Thrombosis was associated with elevated homocysteine levels (OR = 3.8, 95% CI
Introduction
The use of centrally or peripherally inserted venous catheters with implantable ports has become common in cancer patients receiving chemotherapy. Catheters are implanted for the long-term administration of chemotherapy courses with sclerosing agents, in patients with toxic chemotherapy regimens and anticipated haematological toxicity requiring frequent blood sampling and, more recently, in patients who require continuous administration of drug infusions. Many different types of implantable devices consisting of a small-volume subcutaneous injection (s.c.) port (commonly called ports) have been introduced with different types of catheters and devices. Port-associated complications such as infections, thrombosis or even pulmonary embolism, are the cause of significant morbidity and occasionally mortality and remain a significant problem in current daily practice.
Catheter-related thrombosis is probably frequently under-diagnosed as most patients with catheter-related thrombosis are asymptomatic or have non-specific symptoms. The reported incidence of catheter-related venous thrombosis varies considerably, in part due to the method of detecting thrombi, with incidences of greater than 60% being reported (1;2). De Cicco and colleagues (1) reported a very high incidence of 66%, but only 6% of patients with catheter-related thrombosis, screened by venography, were symptomatic.
Lokich and colleagues (3) reported an incidence of 42%, of which 28.3% were symptomatic.
Van Roode and colleagues (4) showed that in patients with haematological malignancies, 26 of 105 patients (25%) developed subclinical thrombosis, of whom nine became clinically manifest. Clinical presentation of catheter-related thrombosis may include arm or head swelling, erythema, pain and congestion of collateral veins, whereas catheter malfunctioning may be the first clinical manifestation of an otherwise asymptomatic catheter-related thrombosis. Thrombosis may lead to prompt catheter removal and anticoagulant treatment.
A hypercoagulable state associated with malignancy, co-morbidity of cancer patients, the use of certain anti-cancer drugs and the presence of a foreign body may contribute to the higher venous thrombosis incidence observed in cancer patients (5). Thrombogenicity of different central venous catheters has been reported to vary depending on the catheter material and size of the catheter used. Polyethylene catheters are associated with a higher incidence than silastic catheters (6;7), whereas there is no difference in the incidence of venous thrombosis following the use of silastic or hydromer-coated polyurethane catheters (6;7).
binnenwerk_m_tesselaar.indd 33 25-1-2008 8:10:30 While several factors may contribute to the development of venous thrombosis, few of these factors have been examined in well-controlled studies (8;9). We therefore investigated various risk factors and the incidence of catheter-related thrombosis in a cohort of cancer patients undergoing chemotherapy and determined the risk of catheterrelated thrombosis associated with anticoagulant treatment and prothrombotic risk factors.
Patients and methods

Patients
Between 
Implantable ports
All catheters implanted were composed of two parts, namely a single lumen radio-opaque catheter connected to an injection reservoir, the port, containing a silicone diaphragm. 
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All catheters were introduced into the veins by experienced interventional radiologists in the angiography interventional radiology suite. Under local anaesthesia, the catheter was tunnelled and a surgeon made the connection between the reservoir and catheter during the same session. After placement, correct positioning of the tip of the catheter was confirmed by chest X-ray and shown to be localised in either the vena cava superior or the right atrium. In general, ports were not immediately removed after cessation of chemotherapy in order to be able to use the ports for second-or third-line chemotherapy, if needed. Experienced nurses flushed all ports every 4-6 weeks with 5 ml of a heparinsodium solution 100 IE/ml and at the end of each cycle of chemotherapy infusions to maintain patency. In patients in whom the port was replaced, the time period of insertion of both catheters was analysed. Chest ports were placed in the subclavian vein, but preferably in the jugular vein. Arm ports were placed in an arm vein. Table 1 Patients with thrombosis n (%) 
Thrombosis and prophylaxis
The diagnosis of symptomatic thrombosis (n = 28), suspected by either symptoms such as arm swelling, pain or bluish discoloration, or suspected because of device malfunctioning (n = 5) was confirmed by duplex ultrasonography or phlebography of the upper extremity venous system, while the investigator was unaware of any antithrombotic medication.
Before 1998 (n = 66), no prophylaxis with anticoagulants was given, but two patients already received anticoagulant treatment with coumarins for various unrelated reasons, e.g., myocardial infarction, recent surgery, and remained on coumarin treatment.
Since 1998, all patients (n = 177) received thrombosis prophylaxis with low molecular weight heparin (LMWH) (nadroparin 2850 IE s.c. daily), except for the three patients who had already received coumarin treatment for other reasons did not receive additional prophylaxis with LMWH. Five patients received a second catheter due to catheter-related thrombosis and received coumarin.
Blood sampling
Since 1999, citrated (room temperature) and acidic citrated blood (on melting ice) samples were obtained from 101 patients, after informed consent was obtained. For factor VIII, IX, XI, G1691A (FV) mutation and G20210A (FII) mutation analysis, blood was collected in tubes containing 0.106 mol/l trisodium citrate. Plasma was prepared by immediate centrifugation for 10 min at 3200 rotations per minute (rpm) and stored at î70°C. DNA was extracted from white cells and the G1691A mutation and G20210A mutation determined by the polymerase chain reaction (PCR). The fibrinogen concentration was determined according to Clauss (10) . Factor VIII: C (11), factor IX: C and factor XI: C levels were measured by a one-stage clotting assay. Elevated levels of factor VIII were defined as >200 IU/dl and of factor IX and factor XI as >150 IU/dl. For homocysteine concentration assays, blood was collected in Stabilyte tubes containing 0.5 mol/l trisodium citrate and plasma was prepared by immediate centrifugation and stored at î70°C. Total homocysteine concentration was determined with the high performance liquid chromatography (HPLC) sodium borohydride / monobromobimane method (NaBH 4 /mBrB method used NaBH 4 for reduction and mBrB derivation) (12). Elevated levels of homocysteine were defined based on the distribution of plasma levels in cohorts with different age and gender. For women, elevated levels of homocysteine were defined as greater than 13.4 mmol/l for those 
Statistical analysis
We compared catheters in patients who experienced catheter-related thrombosis with catheters in patients who did not experience such events.
We investigated putative risk factors by calculating exposure odd ratios (ORs) as an estimate of the relative risk (RR). The ORs show how much higher the risk of disease, e.g., thrombosis, is in the presence of a risk factor than in its absence. An OR ratio of 1 indicates the absence of an association.
Results
Of 243 patients who received 255 devices, in 171 (67%) a catheter was placed in a central vein, i.e., jugular internal or subclavian vein ("chest ports") and in 84 (33%) instances in a peripheral vein, i.e., cubital or basilical vein ("arm ports"). The mean time in situ for the chest ports was 207 days (median 178 days; range 9-1092 days) and for arm ports 352 days (median 321 days; range 7-1795 days).
Thirty-three (14%) of the 243 cancer patients developed a catheter-related thrombosis during chemotherapy; 28 (85%) were associated with patient symptoms and five detected because of device malfunctioning. The mean time until detection of thrombosis was 22 days (median 51 days; range 6-309 days), and eighty-five percent occurred within 2 months. In four of the 28 (14%) thromboses that occurred within 2 months, the port was still functioning.
Except for ovarian cancer, there was no association between tumour type, presence or absence of metastatic disease, platelet count, number of chemotherapeutic cycles or type of chemotherapy and thrombosis incidence (Table 1) . Both arm and chest posts were implanted on the right (n = 152) and left (n = 103) side; the risk of venous thrombosis was 3.5-fold higher for left-sided placement compared with right-sided placement (OR = 3.5, 95% CI 1.6-7.5) ( The position of the tip of the catheter (atrium versus cava superior vein) was associated with the risk of venous thrombosis: the risk was almost 3-fold higher when the catheter tip was located in the superior vena cava compared with the atrium (OR = 2.7, 95% CI 1.1-6.6). We did not find an association with the type of catheter, or the manufacturer. In 8 (5%) of 171 chest ports and 25 (30%) of 84 arm ports, venous thrombosis occurred, i.e., the risk of venous thrombosis was 8-fold higher for arm ports than for chest ports (OR = 8.1 95% CI 3.5-19.1, Table 3 ). a Nadroparin (n = 181) or coumarin (n = 10).
In 64 patients who did not receive anticoagulants, the risk to develop venous thrombosis was similar in patients with arm ports and patients with chest ports; in 13 (28%) of the 46 arm ports, and 6 (33%) of the 18 chest ports, venous thrombosis occurred. 
Discussion
We found an incidence of 14% of catheter-related thrombosis in cancer patients receiving anthracycline-and cisplatin-containing combination chemotherapy via implantable central or peripheral venous ports. Most cases of venous thrombosis occurred within 2 months after insertion of the catheter. The administration of anticoagulants, mainly prophylaxis with s.c. administered nadroparin, was associated with a markedly reduced incidence of thrombosis for chest, but not for arm ports. We identified arm ports, leftsided placement, catheter tip location in the superior cava vein and elevated levels of homocysteine as important risk factors for the development of thrombosis. Most studies on peripherally inserted catheters, although performed in patients with diseases other than cancer, showed a much lower incidence of thrombosis of up to 5% (14) and (15). In agreement with our findings, Kuriakose and colleauges (16) also observed a higher incidence in peripheral ports of 11% compared with 3% in chest ports in patients with mainly cancer or myeloproliferative disorders undergoing chemotherapy.
Left-sided placement as well as location of the catheter tip in the superior vena cava instead of the right atrium was found to be associated with a more than 3-fold respectively 2.6-fold increase in risk for the development of thrombosis. Conflicting data exist in the literature with regard to the association between gene abnormalities and the risk of catheter-related thrombosis in cancer patients. We found no association between the risk for thrombosis and known risk factors for venous thrombosis, nor with elevated levels of factor VIII, IX or XI. This is consistent with our previous data (17) and data from Ramacciotti and colleagues (18) , who also did not find an association between gene polymorphisms tested, i.e., Factor V Leiden, factor II G20210A, factor XIII val 34leu and Methylene tetrahydrofolate reductase (MTHFR) C677T, and the risk of venous thrombosis in cancer patients. In agreement with these findings, Riordan and colleagues In conclusion, this is the first report identifying elevated plasma homocysteine levels as a major risk factor for catheter-related thrombosis. As our study was based on small numbers, further investigation of homocysteine levels in a larger group of cancer patients is warranted to unravel the relationship between factors influencing plasma homocysteine levels in cancer patients undergoing chemotherapy and the occurrence of venous thrombosis. Based on the high incidence of thrombosis in our patient group, despite the use of prophylactic anticoagulants, we strongly advise against the use of arm ports in cancer patients undergoing anthracycline-and/or cisplatin-based combination chemotherapy.
In contrast, the use of a chest port to facilitate administration of such chemotherapy is associated with a low risk of thrombosis, provided that thrombotic prophylaxis is given.
Our data underscore the findings of Monreal and colleagues (2) and Bern and colleagues (26) , with respect to the need for thrombosis prophylaxis in cancer patients with central venous catheters. Conflicting data in the literature with regard to this question may be explained by the absence of stratification for identified prothrombotic risk factors (e.g., elevated levels of homocysteine, arm ports and side of catheter placement) resulting in such factors not being well balanced between the two randomised groups of patients.
